CT 303
Alternative Names: CT-303Latest Information Update: 28 Jan 2025
Price :
$50 *
At a glance
- Originator GC Cell
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Adult respiratory distress syndrome
- No development reported Plaque psoriasis
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for phase-I development in Plaque-psoriasis in South Korea (Parenteral)
- 04 Apr 2023 GC Cell withdrawn a phase I trial in adult respiratory distress syndrome in South Korea due to difficulties in recruiting subjects (NCT05238532)
- 10 Dec 2021 Phase-I clinical trials in Plaque psoriasis in South Korea (Parenteral)